Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. #lymphoma #lymsm https://t.co/dj8UrcG0ii
2,454 followers
390 followers
RT @herbloong: Hot off the #Press! Aside from a new US president elect (congrats!), our analysis of #firstline use of #ceritinib being more…
1,232 followers
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong https://t.co/qtBq7im18V
2,169 followers
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong https://t.co/A0YYSdGGNt